The 4 analysts offering 12-month price forecasts for VistaGen Therapeutics Inc have a median target of 7.50, with a high estimate of 9.00 and a low estimate of 5.00. The median estimate represents a +191.26% increase from the last price of 2.58.
The current consensus among 4 polled investment analysts is to Buy stock in VistaGen Therapeutics Inc. This rating has held steady since May, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.05
Reporting Date Jun 29
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.